Related Experiment Videos
Guido Bendezu-Quispe1, Milton José Max Rodríguez-Zúñiga1, Yuani Miriam Roman1
1Dirección de Evaluación de Tecnologías Sanitarias, Instituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.
Revista Peruana De Medicina Experimental Y Salud Publica
|September 3, 2020
Summary
No current medications effectively treat COVID-19. Rapid reviews found insufficient evidence for therapies like chloroquine or lopinavir/ritonavir, highlighting the need for more clinical trials.
Area of Science:
- Infectious Diseases
- Pharmacology
- Public Health
Background:
- The COVID-19 pandemic necessitated rapid evaluation of potential SARS-CoV-2 therapies.
- Peru's Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) aimed to inform decision-makers.
- Seven therapeutic agents were identified for review.
Purpose of the Study:
- To conduct rapid evidence reviews on therapies for SARS-CoV-2.
- To provide timely information for healthcare professionals and policymakers in Peru.
- To assess the efficacy of specific antiviral and immunomodulatory agents.
Main Methods:
- Conducted rapid evidence reviews using PubMed and Cochrane Library.
- Performed manual searches of health organizations (WHO, CDC) and clinical trial registries.
- Employed a snowball strategy by reviewing reference lists of relevant studies.
Main Results:
- Evaluated chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, oseltamivir, interferon, atazanavir, and anti-SARS-CoV-2 serum.
- As of March 27, 2020, no medication demonstrated sufficient evidence for COVID-19 treatment.
- Identified a lack of high-quality randomized clinical trials.
Conclusions:
- Current evidence does not support recommending any specific medication for COVID-19 treatment.
- High-quality randomized clinical trials are crucial for establishing effective SARS-CoV-2 therapies.
- Further research is essential for informed clinical decision-making during the pandemic.